VKTX

24.7704.14%
GS

Gregory S. Zante

Chief Financial Officer

Mr. Gregory S. Zante, also known as Greg, CPA, serves as Chief Financial Officer at Viking Therapeutics, Inc. since January 4, 2021 and served as Senior Vice President of Finance since August 2019 until January 4, 2021. Mr. Zante served as Vice President of Finance and Operations at Viking Therapeutics, Inc. since December 2016 to July 2019 and its Senior Vice President of Clinical Operations. Mr. Zante was responsible for forecasting, scenario analyses, financing strategies, business development support and operational activities. He served as the Chief Financial Officer and Vice President of Administration at Dance BioPharm Inc. since July 2013 to 2016 and also served as its Principal Accounting Officer. Mr. Zante served as Vice President of Administration and Finance of Sangamo Biosciences, Inc. from August 2003 to June 2013. He served as Senior Director of Administration and Finance of Sangamo Biosciences, Inc. since August 2003 and also served as its Principal Financial Officer until December 2007 and Principal Accounting Officer. Prior to Sangamo, Mr. Zante served as Director of Finance and Administration of Calyx Therapeutics, Inc. from December 2001 to 2003. From October 1993 to December 2001, he held senior financial Managerial positions in several companies including Matrix Pharmaceuticals, Inc. from 2000 to 2001 and Sangamo Therapeutics from 2003 to 2013. He served as a Senior Staff Accountant of Ernst & Young LLP from October 1993 to November 1995. He has accounting and financial experience at public and private companies in the biotechnology and accounting industries. Mr. Zante holds a B.A. in Business Economics and Managerial Accounting from the University of California, Los Angeles. He is a certified public accountant in the State of California and previously served as a senior staff accountant at Ernst & Young.

Positions